Victor Chen 陈昶元

Mr. Chen has served as counsel to:

• LionRock Capital in connection with its acquisition of International Sports Capital S.p.A., which holds 31.05% shares in FC Internazionale Milano S.p.A.
• FountainVest Partners in connection with its going private acquisition of Chinese online career platform Zhaopin Limited, together with Hillhouse Capital and SEEK International*
• FountainVest Partners in a number of transactions, including its establishment of a joint venture in China with WME | IMG, a global sports, fashion and entertainment talent management company, together with Sequoia Capital China and Tencent, and its investments in leading China-based businesses, including Meituan-Dianping, Fangdd.com, and Codoon*
• ZQ Capital in its acquisition of Angiotech Pharmaceuticals, Inc., a medical device manufacturer, and its $210 million PIPE investment in NYSE-listed Nu Skin Enterprises*
• Horizons Ventures Limited, the private investment arm of Li Ka-Shing, in its investments in numerous early-stage technology companies based in the U.S. and Canada*
• Co-investment fund formed by Focus Media and FountainVest Partners in connection with investments in the sports, media and entertainment industries*
• TOM Group Limited, in their investments in WeLab Holdings (WeLend) and Rubikloud Technologies Inc.*
• China Media Capital and FountainVest Partners in their investment in the Greater China business of large-screen movie exhibitor IMAX Corp. (awarded “Mid-Cap Deal of the Year” by Asian Venture Capital Journal (2014)) and the sale of their shares in the Hong Kong IPO of IMAX China*
• the buyer group (including the Carlyle Group, FountainVest Partners, and CITIC Capital Partners) in connection with the US$3.7 billion acquisition of Focus Media, China’s then-largest leveraged buy-out (awarded “Global M&A Deal of the Year: China Private Equity” by The American Lawyer (2014) and “Private Equity Deal of the Year” by IFLR (2014) and China Law & Practice (2013))*
• LionRock Capital in connection with numerous transactions*
• Goldman Sachs as financial adviser to the Special Committee of NASDAQ-listed AsiaInfo-Linkage in a US$890 million going-private acquisition led by CITIC Capital Partners*
• Lazard as financial adviser to the buyer group in its going-private acquisition of NASDAQ-listed Yucheng Technologies Limited*
• the private equity buyer consortium in its going-private acquisition of China jewelry retailer and distributor NASDAQ-listed LJ International*
• the Special Committee of NASDAQ-listed CNinsure in connection with a proposed US$950 million going-private transaction involving its chairman and private equity sponsors, including TPG*
• the independent board of NYSE-listed Acorn International, a China-based TV retailer, in connection with its consideration of an unsolicited partial tender offer by its co-founders*
• the founder and controlling shareholder of Tiens Biotech Group in a going-private squeeze-out merger transaction*
• the Special Committee of Board of Directors of NASDAQ-listed Solarfun Power Holdings, a solar cell producer, in connection with its US$370 million sale of a controlling stake to Hanwha Corporation*
• Sequoia Capital, Citic Capital and FountainVest Partners in a US$180 million PIPE investment in NASDAQ-listed SINA Corporation*
• NYSE-listed WuXi Pharmatech, a leading Chinese R&D outsourcing company, in its announced (and subsequently terminated) acquisition by Charles River Laboratories for US$1.6 billion*
• NYSE-listed Mindray Medical International Limited, a China-based medical device company, in its US$202 million acquisition of the worldwide patient monitoring business of Datascope, creating the then-third-largest player in the global patient monitoring industry*

* Denotes experience prior to joining Goodwin.